Heather Murphy
Family · Boston, MANPI 1568983633
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,540 of the $6,804 with a category attached, or 81.4%. It is spread thinly across 22 manufacturers, the largest accounting for just 18.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $3,000 and has fallen 75.7% since, to $730 in 2025. Among family clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 81 payments — averaging $84.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Fresenius Kabi USA, LLC$1K
- GSK$932
- Daiichi Sankyo Inc.$666
- AstraZeneca$498
- Eisai Inc.$443
- Gilead$426
- plus $3K from 16 others
What the payments were for
- Consulting fees$1,01315%
- Food & beverage$5,54081%
- Education$2514%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Fresenius Kabi USA, LLC | 3 | $1,237 |
| GSK | 18 | $932 |
| Daiichi Sankyo Inc. | 5 | $666 |
| AstraZeneca | 5 | $498 |
| Eisai Inc. | 4 | $443 |
| Gilead | 6 | $426 |
| Stemline Therapeutics Inc. | 6 | $412 |
| Tactile Systems Technology Inc | 5 | $351 |
| Lilly USA, LLC | 4 | $307 |
| Puma Biotechnology, Inc. | 4 | $278 |
| Servier Pharmaceuticals LLC | 2 | $243 |
| Merck | 7 | $206 |
| Exelixis Inc. | 1 | $121 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $119 |
| Mirati Therapeutics, Inc. | 1 | $112 |
| Seagen Inc. | 1 | $99 |
| Genentech, Inc. | 2 | $93 |
| Amgen | 1 | $89 |
| Genentech USA, Inc. | 2 | $74 |
| Johnson & Johnson | 1 | $50 |
| AVEO Pharmaceuticals, Inc. | 1 | $25 |
| Geron Corporation | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,804 in reported general payments places this provider in the 95th percentile of 2,320 family providers in Massachusetts.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IbrancePalbociclib | 16 | $246,185 |
| KisqaliRibociclib Succinate | 17 | $227,376 |
| EliquisApixaban | 26 | $14,670 |
| Exemestane | 43 | $6,075 |
| Anastrozole | 303 | $5,212 |
| Tamoxifen Citrate | 117 | $3,733 |
| Letrozole | 102 | $2,702 |
| Raloxifene Hcl | 14 | $1,421 |
| Nystatin | 15 | $131 |
Paid to pharmacies, not to this prescriber.
Other family in Boston
- Brittany MurrayBoston$141K
- Naomi AmudalaBoston$79K
- Alexa CostaBoston$17K
- Caitlin MurphyBoston$16K
- Alison KrustapentusBoston$7K
- Lisa LopesBoston$6K
- Kathryn QuinnBoston$6K
- Elizabeth KruegerBoston$6K
- Paul GouldLakeville$343K
- Jennifer FlemingLawrence$80K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.